Befunolol

DB09013ExperimentalSmall molecule

Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

Chemical structure of Befunolol
Primary indication
Used in the management of open angle glaucoma.Curator reviewed
Formula / weight
C16H21NO4 · 291.347 g/mol (avg)

Resolves to

Compound
UNII418546MT3ACAS39552-01-7ChEMBLCHEMBL153984ChEBI135212PubChem2309KEGGD07496
Clinical / RWD
ATCS01ED06
Structure
InChIKeyZPQPDBIHYCBNIG-UHFFFAOYSA-NSMILESCC(C)NCC(O)COC1=CC=CC2=C1OC(=C2)C(C)=O
Targets
P08588ADRB1P07550ADRB2

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
25Drug interactionsStructured to mechanism, not free text
Sign in
2Marketed productsAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 17 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Befunolol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In